
Delving Deeper into Green Hedgehog Solutions
Sustainability
How do you determine which energy-efficient upgrades to recommend to building owners? We are technology and product agnostic. We look at anything and everything that can be improved. We’re not coming at it from an equipment supplier’s perspective or a software supplier’s perspective. We’re coming at it from the owner’s perspective and saying, “What and…
Author: Sadiq Currimbhoy
Date: June 23, 2023
- Interviewer: Ana Gomes, Vulpes Corporate Communications
- Interviewee: Tienyu Sieh, Co-Founder of Green Hedgehog Solutions and Founder of Blue Sky Energy Efficiency Asia
- Recorded: Friday, 9th of June 2023
1. How do you determine which energy-efficient upgrades to recommend to building owners?
We are technology and product agnostic. We look at anything and everything that can be improved. We’re not coming at it from an equipment supplier’s perspective or a software supplier’s perspective. We’re coming at it from the owner’s perspective and saying, “What and where are the opportunities?” We’re completely open and take a completely holistic approach to identifying how to make a building more efficient. We rely on different technical partners, such as equipment suppliers, engineering consultants, and the building’s facility management team. Our additional layer is to translate that into an economically viable opportunity and to manage that risk. We identify opportunities through partnerships and then add to that to make it happen.
2. What parameters go into your assessment?
The first and most important parameter is that the savings have to be measurable. We’re not talking about “feel good” savings. We’re talking about actual savings that can be measured and verified from an engineering perspective. That’s the most important. We need to baseline the existing conditions and measure the savings that have been delivered by the projects that we support.
3. How do you ensure that the energy savings generated are accurately measured and verified?
There’s a common practice called IPMVP[1], which is an international protocol recognized and accepted by the professional engineering bodies that work in this space. They have a set of protocols to determine what the baseline is and how to measure the savings. They’ve applied this many times in many different circumstances and updated those protocols to reflect their experiences. We adopt best practices.
4. Have you encountered any operational challenges in your past projects?
Every building is unique, and so there are always challenges. We’re not trying to solve the engineering challenges at our level. We rely on our engineering partners to come to us and say that they have a reliable operational solution. Where we focus on is debugging the financial and risk aspects of these projects to make sure that they can fit with the owner or the operator’s requirements and to ensure that the funding is not an obstacle.
5. How are you able to keep up to date with all the latest innovation and technical developments?
Our priority is not necessarily to be at the bleeding edge of technology, but rather a fast follower. We’re not here to fund experimental technologies that haven’t been proven or that don’t have a track record. We’re relatively risk averse in terms of trying to implement solutions that not only we feel comfortable with, but we want our building owner, our building operators to be extra comfortable with. They’re not guinea pigs in any respect. We work with technical partners who have a strong track record and rely on them to do good work.
We work with companies that have a blue-chip track record with blue-chip customers and apply that to our clients. Sometimes the opportunity simply lies in the fact that some of our clients might not want to engage what they see as overkill engineering resources to solve a problem. But we’re here to make sure that the risk is taken off the table, and we can incorporate those costs into our assessment to say, “Look, it may cost a little bit more, but the value they bring is quantifiable and worth it.”
[1] https://evo-world.org/en/products-services-mainmenu-en/protocols/ipmvp
Disclaimer
Disclaimers and Important Notes
This information (“Information”) is for private use, for information and discussion purposes only. The Information is not and does not constitute, and under no circumstances should it be considered as or intended to form part of any offer, recommendation, invitation or solicitation to subscribe to or to enter into any transaction, nor is it calculated to invite or permit the making of offers to the public to subscribe to or enter into any transaction and should not be viewed as such. The Information does not intend to express any opinion on the merits of buying, selling or holding a particular investment product or a class of investment products.
This is not investment research and it is for information only. It should not be relied upon as financial advice. It has not been prepared in accordance with legal requirements designed to promote the independence of research, it is not intended to constitute independent, impartial or objective research analysis or recommendations and should not be treated or relied on as such. The provision of this Information is not regulated by any regulatory authority, including the Monetary Authority of Singapore, or under any regulation, including the Financial Advisors Act of Singapore and the Securities and Futures of Singapore. Notwithstanding this, the Information is not presented with the intention of inducing a person to buy, sell or hold a particular investment product or a class of investment products. Any terms, conditions and opinions contained herein may have been obtained from various sources and neither “Vulpes” nor any of its related companies or affiliates nor any of their respective directors or employees make any warranty, expressed or implied, as to its accuracy or completeness and thus assume no responsibility for it.
The Information may be subject to further revision, verification and updating and Vulpes undertakes no responsibility thereof. All figures and amounts stated are for illustration purposes only and shall not bind Vulpes. Vulpes does not act as an adviser and is not in the business of providing financial advice. Vulpes assumes no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any arrangement or entrance into any transaction in reliance on the information contained herein. This Information is generic and is not intended to provide personal investment advice and does not take into account the specific investment objectives, the financial situation and the particular needs of persons who may receive or read this Information. Investors should therefore seek financial, legal and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed in the Information. The Information may contain forward looking statements which are often but not always identified by the use of words such as “anticipate”, “believe”, “estimate”, “intend”, “plan”, “expect”, “forecast”, “predict” and “project” and statements that an event or result “may”, “will”, “can”, “should”, “could” or “might” occur or be achieved and other similar expressions. Such forward looking statements are based on assumptions made and information currently available to us and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those expressed in any forward-looking statements. Readers are cautioned not to place undue relevance on these forward-looking statements. Vulpes expressly disclaims any obligation to update or revise any such forward looking statements to reflect new information, events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.
All information, estimates, forecasts and opinions included in this document may be subject to change without notice. Changes in market conditions or in any assumptions may have a material impact on any estimates or opinion stated. In any event, past performance is no guarantee of future results, and future results may not meet expectations due to a variety of economic, market and other factors. Any information relating to past performance, or any future forecast based on past performance or other assumptions, is not necessarily a reliable indicator of future results. If the Information has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of the Information, which may arise as a result of electronic transmission. The Information is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Without prejudice to the foregoing, the reader is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.
Country Specific Notices
United Kingdom: This document does not constitute an offer or invitation to purchase or subscribe for any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with or act as an inducement to enter into any contract or commitment whatsoever.
This document is only addressed to and directed at persons resident in the United Kingdom and who are “Qualified Investors” within the meaning of article 2(e) of The Prospectus Regulation (EU) 2017/1129 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) (“Qualified Investors”). In addition, in the United Kingdom, this document has not been approved by an authorised person pursuant to section 21 of the Financial Services and Markets Act 2000 (“FSMA”) and, as such, this document is being distributed only to, and is directed only at, qualified investors (i) who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2005 (the “Order”) or are Qualified Investors falling within article 49 of the Order, and (ii) to whom the information may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The information in this document must not be acted on or relied on in the United Kingdom, by persons who are not relevant persons. This document must not be acted on or relied on in the United Kingdom, by persons who are not both Relevant Persons and Qualified Investors.
United States of America: This document is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not intended to create legal relations on the basis of information provided herein.
Singapore: If this document is distributed in Singapore, it is made available through general information circulation only it is not intended as an offer or solicitation for the purchase or sale of any securities, financial instrument or product or to provide financial services. It is not intended to create legal relations on the basis of information provided herein. The contents of the Materials have not been reviewed by in the Monetary Authority of Singapore.
South Africa: This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. The views in this publication are those of the author(s) and are subject to change and “Vulpes” has no obligation to update its opinions or the information in this publication. If this publication contains recommendations, those recommendations reflect solely and exclusively those of the author(s) and such opinions were prepared independently of any other interests. This publication does not constitute personal investment advice.
Read more insights

SCANCELL HOLDINGS PLC: Scope 2 melanoma trial beats milestones
Life Sciences
Scancell’s Phase 2 SCOPE trial for advanced melanoma impressed – with Initial data from 11…
Author: Jamshed Dadabhoy
Date: September 23, 2023